• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
To JUPITER and beyond: statins, inflammation, and primary prevention.迈向JUPITER研究及更远：他汀类药物、炎症与一级预防。
Crit Care. 2010;14(3):310. doi: 10.1186/cc9006. Epub 2010 May 13.
2
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.瑞舒伐他汀、炎症、C反应蛋白、JUPITER研究与心血管疾病的一级预防——一种观点
Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812.
3
JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.JUPITER研究及其卫星研究：JUPITER研究及其二次分析的临床意义。
World J Cardiol. 2011 Jul 26;3(7):207-14. doi: 10.4330/wjc.v3.i7.207.
4
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.对于高敏 C 反应蛋白升高或血脂异常的女性，用他汀类药物进行心血管一级预防：来自评估瑞舒伐他汀用于预防的应用（JUPITER）的干预试验和来自一级预防试验的女性亚组的荟萃分析的结果。
Circulation. 2010 Mar 9;121(9):1069-77. doi: 10.1161/CIRCULATIONAHA.109.906479. Epub 2010 Feb 22.
5
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?他汀类药物用于一级预防的理由：一项评估瑞舒伐他汀的干预试验（JUPITER）——C反应蛋白能否用于指导一级预防中的他汀类药物治疗？
Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1.
6
Impact of the JUPITER trial on statin prescribing for primary prevention.JUPITER 试验对他汀类药物用于一级预防的处方影响。
Pharmacotherapy. 2014 Jan;34(1):9-18. doi: 10.1002/phar.1340. Epub 2013 Aug 12.
7
Extreme all-cause mortality in JUPITER requires reexamination of vital records.JUPITER研究中极高的全因死亡率需要重新审查生命记录。
Cardiology. 2011;120(2):84-8. doi: 10.1159/000330507. Epub 2011 Dec 2.
8
[Primary prevention trials performed with statins prior to the JUPITER trial].[在JUPITER试验之前使用他汀类药物进行的一级预防试验]
Turk Kardiyol Dern Ars. 2009 Apr;37 Suppl 4:14-7.
9
C-Reactive Protein: How Has JUPITER Impacted Clinical Practice?C反应蛋白：JUPITER研究如何影响临床实践？
Ochsner J. 2009 Winter;9(4):204-10.
10
Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.瑞舒伐他汀与JUPITER试验：对一级预防星系中一颗无生命星球的批判性评估。
Int J Occup Environ Health. 2012 Jan-Mar;18(1):70-8. doi: 10.1179/1077352512Z.0000000008.

引用本文的文献

1
Relationship between high-sensitivity C-reactive protein serum levels and the severity of coronary artery stenosis in patients with coronary artery disease.冠心病患者血清高敏C反应蛋白水平与冠状动脉狭窄程度的关系
ARYA Atheroscler. 2016 Sep;12(5):231-237.
2
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies.他汀类药物通过靶向多泡体影响内皮细胞趋化因子的呈现。
PLoS One. 2012;7(7):e40673. doi: 10.1371/journal.pone.0040673. Epub 2012 Jul 16.
3
Prognostic impact of baseline high-sensitivity C-reactive protein in patients with acute myocardial infarction undergoing percutaneous coronary intervention based on body mass index.基于体重指数的经皮冠状动脉介入治疗急性心肌梗死患者基线高敏 C 反应蛋白对预后的影响。
Korean Circ J. 2012 Mar;42(3):164-72. doi: 10.4070/kcj.2012.42.3.164. Epub 2012 Mar 26.
4
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.瑞舒伐他汀、炎症、C反应蛋白、JUPITER研究与心血管疾病的一级预防——一种观点
Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812.

本文引用的文献

1
Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial).阿托伐他汀40毫克/天降低病房患者脓毒症严重程度的随机双盲安慰剂对照试验（脓毒症试验）
Crit Care. 2012 Dec 11;16(6):R231. doi: 10.1186/cc11895.
2
Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial.辛伐他汀抑制羟甲基戊二酰辅酶 A 还原酶治疗急性肺损伤以减轻肺功能障碍（HARP-2）试验：一项随机对照试验的研究方案。
Trials. 2012 Sep 17;13:170. doi: 10.1186/1745-6215-13-170.
3
Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.C-反应蛋白升高的成年人血管事件预防中他汀类药物治疗的成本效益：JUPITER 的意义。
Curr Med Res Opin. 2010 Oct;26(10):2485-97. doi: 10.1185/03007995.2010.516994.
4
Statins for sepsis: a critical and updated review.用于脓毒症的他汀类药物：一项批判性的最新综述。
Clin Microbiol Infect. 2009 Apr;15(4):325-34. doi: 10.1111/j.1469-0691.2009.02750.x.
5
A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis.脓毒症重症患者阿托伐他汀血浆浓度的初步研究。
Intensive Care Med. 2009 Apr;35(4):717-21. doi: 10.1007/s00134-008-1358-3. Epub 2008 Nov 26.
6
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.瑞舒伐他汀预防C反应蛋白升高的男性和女性发生血管事件。
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
7
Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.出院时的炎症标志物可预测肺炎和脓毒症后的后续死亡率。
Am J Respir Crit Care Med. 2008 Jun 1;177(11):1242-7. doi: 10.1164/rccm.200712-1777OC. Epub 2008 Mar 27.
8
Statin treatment after onset of sepsis in a murine model improves survival.在小鼠模型中，脓毒症发作后进行他汀类药物治疗可提高生存率。
Circulation. 2005 Jul 5;112(1):117-24. doi: 10.1161/CIRCULATIONAHA.104.502195.
9
HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.HMG-CoA还原酶抑制剂辛伐他汀可显著提高脓毒症小鼠模型的存活率。
Circulation. 2004 Jun 1;109(21):2560-5. doi: 10.1161/01.CIR.0000129774.09737.5B. Epub 2004 May 3.
10
Statins, inflammation, and sepsis: hypothesis.他汀类药物、炎症与脓毒症：假说
Chest. 2003 Aug;124(2):740-3. doi: 10.1378/chest.124.2.740.

To JUPITER and beyond: statins, inflammation, and primary prevention.

作者信息

Rao Ajay D, Milbrandt Eric B

机构信息

Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

出版信息

Crit Care. 2010;14(3):310. doi: 10.1186/cc9006. Epub 2010 May 13.

DOI:10.1186/cc9006
PMID:20497597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2911709/
Abstract
摘要